Initial report of the use of an injectable porcine collagen-derived matrix to stimulate healing of diabetic foot wounds in humans

Wound Repair and Regeneration

Volumn 13, Issue 3, 2005, Pages 243-247

  Marston, William A ^a   Isala, Anton ^b   Hill, Ronald S ^b   Mendes, Robert ^a   Minsley, Mary Ann ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b Encelle Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN DERIVATIVE; E MATRIX; MATRIX PROTEIN; SCAFFOLD PROTEIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC FOOT; HUMAN; MALE; PILOT STUDY; PRIORITY JOURNAL; TREATMENT OUTCOME; WOUND HEALING;

AGED; BIOLOGICAL PRODUCTS; COLLAGEN; DEXTRANS; DIABETIC FOOT; DRUG COMBINATIONS; FEASIBILITY STUDIES; HUMANS; INJECTIONS, INTRALESIONAL; MALE; MIDDLE AGED; PILOT PROJECTS; WOUND HEALING;

EID: 20544448964     PISSN: 10671927     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1067-1927.2005.130305.x     Document Type: Article

References (15)

1. Armstrong DG, Lavery LA. Diabetic foot ulcers: prevention, diagnosis, and classification. Am Fam Physician 1998;57:1325-32.
2. Veves A, Akbari CM, Primavera J, Donaghue VM, Zacharoulis D, Chrzan JS, DeGirolami U, LoGerfo FW, Freeman R. Endothelial dysfunction and the expression of endothelial nitric oxide synthetase in diabetic neuropathy, vascular disease, and foot ulceration. Diabetes 1998;47:457-63.
3. Jorneskog G, Brismar K, Fagrell B. Skin capillary circulation is more impaired in the toes of diabetic than non-diabetic patients with peripheral vascular disease. Diabet Med 1995;12:36-41.
4. Ramsey SD, Newton K, Blough D, McCulloch DK, Sandhu N, Reiber GE, Wagner E. Incidence, outcomes, and cost of foot ulcers in patients with diabetes. Diabetes Care 1999;22:382-7.
5. Weiman TJ, Smiell JM, Su Y. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (Becaplermin) in patients with chronic neuropathic diabetic ulcers. Diabetes Care 1998;21:822-7.
6. Veves A, Falanga V, Armstrong DG, Sabolinski ML. Graftskin, a human skin equivalent, is effective in the management of noninfected neuropathic diabetic foot ulcers: a prospective randomized multicenter clinical trial. Diabetes Care 2001;24:290-5.
7. Gentzkow GD, Jensen JL, Polak RA. Improved healing of diabetic foot ulcers after grafting with a living human dermal replacement. Wounds 1999;11:77-84.
8. Smith LT, Holbrook KA. Development of dermal connective tissue in human embryonic and fetal skin. Scan Electron Microsc 1982;4:1745-51.
9. Klann R, Lloyd W, Lacy S. A novel hydrogel copolymer reduces scar formation and increases TGF β3 gene expression. Presented at the 15th Annual Symposium on Advanced Wound Care. Baltimore, MD, April 29, 2002.
10. Safety data on file in FDA, submission. Encelle, Inc.
11. Usala AL. Methods for increasing vascularization and promoting wound healing. US Patent #6,261,387; issued July 17, 2001.
12. Ribbons KA, Currie MG, Conner JR, Manning PT, Allen PC, Didier P, Ratterree MS, Clark DA, Miller MJ. The effect of inhibitors of inducible nitric oxide synthase on chronic colitis in the rhesus monkey. J Pharmacol Exp Ther 1997;280:1008-15.
13. Usala AL, Dudek R, Lacy S, Olson J, Penland S, Sutton J, Ziats NP, Hill RS. Induction of fetal-like wound repair mechanisms in vivo with a novel matrix scaffolding. Diabetes 2001;50 (Suppl. 2):A488.
14. Kantor J, Margolis DJ. Expected healing rates for chronic wounds. Wounds 2000;12:155-8.
15. Lovvorn HN, Cheung DT, Nimni ME, Perelman N, Estes JM. Relative distribution and cross-linking of collagen distinguish fetal from adult sheep wound repair. J Ped Surg 1999;34:218-23.